You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOlopatadine
Accession NumberDB00768  (APRD00310)
TypeSmall Molecule
GroupsApproved
DescriptionUsed to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.
Structure
Thumb
Synonyms
Olopatadin
Olopatadina
Olopatadine
Olopatadinum
Opatanol
External Identifiers
  • ALO 4943 A
  • KW 4679
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Olopatadine 0.1%Solution0.1 %OphthalmicActavis Pharma Company2013-12-06Not applicableCanada
Act Olopatadine 0.2%Solution0.2 %OphthalmicActavis Pharma Company2014-02-20Not applicableCanada
Jamp-olopatadineSolution0.1 %OphthalmicJamp Pharma CorporationNot applicableNot applicableCanada
Mint-olopatadineSolution0.1 %OphthalmicMint Pharmaceuticals Inc2014-07-29Not applicableCanada
Olopatadine HydrochlorideSpray, metered665 ug/100uLNasalSandoz Inc.2012-06-30Not applicableUs
Olopatadine HydrochlorideSolution / drops1 mg/mLOphthalmicSandoz Inc.2015-09-15Not applicableUs
Olopatadine Hydrochloride NasalSpray665 ug/1NasalPerrigo New York Inc2015-04-01Not applicableUs
Olopatadine Ophthalmic SolutionSolution0.1 %OphthalmicBeximco Pharmaceuticals Canada LimitedNot applicableNot applicableCanada
PatadaySolution / drops2 mg/mLOphthalmicLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-03Not applicableUs
PatadaySolution / drops2 mg/mLOphthalmicPhysicians Total Care, Inc.2011-01-03Not applicableUs
PatadaySolution / drops2 mg/mLOphthalmicAlcon Laboratories, Inc.2007-02-15Not applicableUs
PatadaySolution0.2 %OphthalmicAlcon Canada Inc2011-04-14Not applicableCanada
PatanaseSpray, metered665 ug/1NasalPhysicians Total Care, Inc.2009-07-13Not applicableUs
PatanaseSpray, metered665 ug/1NasalClinical Solutions Wholesale2008-04-28Not applicableUs
PatanaseSpray, metered600 ug/1NasalAlcon Laboratories, Inc.2008-04-28Not applicableUs
PatanolSolution / drops1 mg/mLOphthalmicAlcon Laboratories, Inc.1997-02-17Not applicableUs
PatanolSolution / drops1 mg/mLOphthalmicA S Medication Solutions1997-02-17Not applicableUs
PatanolSolution / drops1 mg/mLOphthalmicPhysicians Total Care, Inc.2002-05-08Not applicableUs
Patanol Ophthalmic SolutionLiquid0.1 %OphthalmicAlcon Canada Inc1998-02-09Not applicableCanada
PazeoSolution0.7 %OphthalmicAlcon Canada IncNot applicableNot applicableCanada
PazeoSolution7 mg/mLOphthalmicAlcon Laboratories, Inc.2015-01-29Not applicableUs
Sandoz OlopatadineSolution0.1 %OphthalmicSandoz Canada Incorporated2013-02-04Not applicableCanada
Sandoz Olopatadine 0.2%Solution0.2 %OphthalmicSandoz Canada Incorporated2014-02-24Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-olopatadineSolution0.2 %OphthalmicApotex Inc2014-04-10Not applicableCanada
Apo-olopatadineSolution0.1 %OphthalmicApotex Inc2013-07-26Not applicableCanada
Olopatadine HydrochlorideSolution / drops1.11 mg/mLOphthalmicNovel Laboratories, Inc.2015-12-072016-10-13Us
Olopatadine HydrochlorideSolution / drops1 mg/mLOphthalmicRising Pharmaceuticals, Inc.2015-12-07Not applicableUs
Olopatadine HydrochlorideSolution / drops1 mg/mLOphthalmicPreferred Pharmaceuticals Inc.2016-10-10Not applicableUs
Olopatadine HydrochlorideSolution / drops1 mg/mLOphthalmicAlvogen Inc.2015-12-08Not applicableUs
Olopatadine HydrochlorideSolution / drops1 mg/mLOphthalmicAurobindo Pharma Limited2015-12-18Not applicableUs
Olopatadine HydrochlorideSolution / drops1.11 mg/mLOphthalmicSomerset Therapeutics, Llc2016-06-29Not applicableUs
Olopatadine HydrochlorideSolution / drops1 mg/mLOphthalmicApotex Corp.2015-12-07Not applicableUs
Olopatadine HydrochlorideSpray, metered665 ug/1NasalApotex Corp.2014-10-27Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlchekApex
AlerchekIndoco
AllelockDae Woong
OpatanolAlcon
Patanol SAlcon
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Olopatadine Hydrochloride
140462-76-6
Thumb
  • InChI Key: HVRLZEKDTUEKQH-NOILCQHBSA-N
  • Monoisotopic Mass: 373.144471346
  • Average Mass: 373.873
DBSALT000685
Categories
UNIID27V6190PM
CAS number113806-05-6
WeightAverage: 337.4122
Monoisotopic: 337.167793607
Chemical FormulaC21H23NO3
InChI KeyJBIMVDZLSHOPLA-LSCVHKIXSA-N
InChI
InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-
IUPAC Name
2-[(2Z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-5-yl]acetic acid
SMILES
CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2
Pharmacology
IndicationFor the treatment of ocular itching associated with allergic conjunctivitis.
Structured Indications
PharmacodynamicsUsed to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.
Mechanism of actionOlopatadine is a selective histamine H1 antagonist that binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Histamine H1 receptorProteinyes
antagonist
HumanP35367 details
Protein S100-A1Proteinunknown
antagonist
HumanP23297 details
Protein S100-A12Proteinunknown
antagonist
HumanP80511 details
Protein S100-BProteinunknown
other/unknown
HumanP04271 details
Protein S100-A13Proteinunknown
other/unknown
HumanQ99584 details
Protein S100-A2Proteinunknown
antagonist
HumanP29034 details
Related Articles
AbsorptionOphthalmic use of olopatadine usually does not produce measurable plasma concentrations.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

The mono-desmethyl and the N-oxide metabolites have been detected at low concentrations in the urine.

SubstrateEnzymesProduct
Olopatadine
Not Available
Mono-desmethyl olopatadineDetails
Olopatadine
Not Available
Olopatadine n-oxideDetails
Route of eliminationElimination was predominantly through renal excretion.
Half life3 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Olopatadine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Olopatadine is combined with 19-norandrostenedione.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Olopatadine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Olopatadine.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Olopatadine.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Olopatadine is combined with 4-Androstenedione.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Olopatadine.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Olopatadine is combined with 5-androstenedione.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Olopatadine.Experimental
AbciximabOlopatadine may increase the anticoagulant activities of Abciximab.Approved
AcebutololOlopatadine may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Aceclofenac.Approved
AcenocoumarolOlopatadine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Olopatadine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Olopatadine.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinOlopatadine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Olopatadine.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Olopatadine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Olopatadine.Approved, Investigational
AlclometasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alendronic acid.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Olopatadine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Olopatadine.Approved, Illicit
AliskirenOlopatadine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Olopatadine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Olopatadine.Approved, Illicit, Investigational
AlprenololOlopatadine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Olopatadine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Amcinonide.Approved
AmikacinOlopatadine may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideOlopatadine may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Olopatadine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Olopatadine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Olopatadine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Olopatadine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Olopatadine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Olopatadine.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Olopatadine.Approved, Illicit
AmrubicinOlopatadine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodOlopatadine may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Olopatadine is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Anisodamine.Investigational
annamycinOlopatadine may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Antipyrine.Approved
Antithrombin III humanOlopatadine may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Olopatadine may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanOlopatadine may increase the anticoagulant activities of Apixaban.Approved
ApramycinOlopatadine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Olopatadine is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Olopatadine can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinOlopatadine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinOlopatadine may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanOlopatadine may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Olopatadine.Approved, Investigational
ArotinololOlopatadine may decrease the antihypertensive activities of Arotinolol.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Olopatadine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Olopatadine.Approved
AtazanavirThe metabolism of Olopatadine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololOlopatadine may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Olopatadine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Olopatadine.Vet Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Azapropazone.Withdrawn
AzelastineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Olopatadine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Olopatadine.Approved
BalsalazideOlopatadine may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Olopatadine.Illicit
BecaplerminOlopatadine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololOlopatadine may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Olopatadine.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Olopatadine.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Benoxaprofen.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Olopatadine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Olopatadine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Olopatadine.Approved
Benzylpenicilloyl PolylysineOlopatadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Olopatadine.Investigational
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Olopatadine.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Betamethasone.Approved, Vet Approved
BetaxololOlopatadine may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Betulinic Acid.Investigational
BevantololOlopatadine may decrease the antihypertensive activities of Bevantolol.Approved
BexaroteneThe serum concentration of Olopatadine can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Olopatadine.Approved, Investigational
BisoprololOlopatadine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinOlopatadine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Olopatadine can be decreased when combined with Boceprevir.Approved
BopindololOlopatadine may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Olopatadine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Olopatadine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Olopatadine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Olopatadine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Olopatadine.Approved, Illicit
BromfenacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bromfenac.Approved
BrompheniramineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Olopatadine.Approved, Withdrawn
BucillamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bucillamine.Investigational
BucindololOlopatadine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Budesonide.Approved
BufuralolOlopatadine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideOlopatadine may decrease the diuretic activities of Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Olopatadine.Approved, Investigational
BupranololOlopatadine may decrease the antihypertensive activities of Bupranolol.Approved
BuprenorphineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Olopatadine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Olopatadine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Olopatadine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Olopatadine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Olopatadine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Olopatadine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Olopatadine.Approved, Illicit, Vet Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Olopatadine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Olopatadine.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Olopatadine.Approved
CarbamazepineThe metabolism of Olopatadine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Olopatadine.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Olopatadine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Olopatadine.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Olopatadine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololOlopatadine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolOlopatadine may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Celecoxib.Approved, Investigational
CeliprololOlopatadine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Olopatadine can be increased when it is combined with Ceritinib.Approved
CertoparinOlopatadine may increase the anticoagulant activities of Certoparin.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Olopatadine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Olopatadine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Olopatadine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Olopatadine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Olopatadine.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Olopatadine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olopatadine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Olopatadine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Olopatadine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Olopatadine.Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Olopatadine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Olopatadine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Olopatadine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Olopatadine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Olopatadine.Approved, Vet Approved
CinoxacinOlopatadine may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinOlopatadine may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CitalopramThe risk or severity of adverse effects can be increased when Olopatadine is combined with Citalopram.Approved
Citric AcidOlopatadine may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Olopatadine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Olopatadine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Olopatadine.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clodronate.Approved, Investigational, Vet Approved
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Olopatadine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Olopatadine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Olopatadine.Vet Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Olopatadine.Approved, Illicit
ClotrimazoleThe metabolism of Olopatadine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Olopatadine.Approved
CobicistatThe metabolism of Olopatadine can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Olopatadine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Olopatadine.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Olopatadine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Olopatadine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Olopatadine can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cortisone acetate.Approved
CrizotinibThe metabolism of Olopatadine can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Olopatadine is combined with Curcumin.Investigational
CyclizineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Olopatadine.Approved
CyclosporineOlopatadine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Olopatadine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Olopatadine.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Olopatadine is combined with D-Limonene.Investigational
Dabigatran etexilateOlopatadine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Olopatadine can be decreased when it is combined with Dabrafenib.Approved
DalteparinOlopatadine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidOlopatadine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DantroleneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Olopatadine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Olopatadine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Olopatadine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinOlopatadine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe serum concentration of Olopatadine can be decreased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Olopatadine is combined with dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Olopatadine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Olopatadine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Olopatadine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desipramine.Approved
DesirudinOlopatadine may increase the anticoagulant activities of Desirudin.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Olopatadine.Vet Approved
DexamethasoneThe serum concentration of Olopatadine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dexamethasone isonicotinate.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Olopatadine.Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Olopatadine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Olopatadine.Approved, Vet Approved
DextranOlopatadine may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Olopatadine may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Olopatadine may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Olopatadine may increase the anticoagulant activities of Dextran 75.Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Olopatadine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Olopatadine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Olopatadine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Olopatadine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Olopatadine.Approved, Illicit, Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Olopatadine.Approved, Vet Approved
DicoumarolOlopatadine may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionDiethylpropion may decrease the sedative activities of Olopatadine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Difenoxin.Approved, Illicit
DiflorasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Olopatadine is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Olopatadine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Olopatadine.Approved, Illicit
DihydroergotamineThe metabolism of Olopatadine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Olopatadine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Olopatadine.Experimental, Illicit
DihydrostreptomycinOlopatadine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DiltiazemThe metabolism of Olopatadine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dimenhydrinate.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Olopatadine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Olopatadine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Olopatadine.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Olopatadine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Olopatadine.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Olopatadine.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Doxepin.Approved
DoxorubicinOlopatadine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineThe metabolism of Olopatadine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Olopatadine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved, Illicit
DronedaroneThe metabolism of Olopatadine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved, Vet Approved
DrospirenoneOlopatadine may increase the hyperkalemic activities of Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Olopatadine.Experimental, Illicit
DroxicamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Droxicam.Approved
DuloxetineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Duvelisib.Investigational
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Olopatadine.Approved
E6201The risk or severity of adverse effects can be increased when Olopatadine is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ebselen.Investigational
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Olopatadine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Olopatadine.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ecopipam.Investigational
Edetic AcidOlopatadine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanOlopatadine may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of Olopatadine can be decreased when it is combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Olopatadine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Olopatadine.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Olopatadine.Approved, Vet Approved
EnoxacinOlopatadine may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinOlopatadine may increase the anticoagulant activities of Enoxaparin.Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Olopatadine.Approved, Investigational
EnzalutamideThe serum concentration of Olopatadine can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Olopatadine is combined with Epirizole.Approved
EpirubicinOlopatadine may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneOlopatadine may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Olopatadine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Olopatadine.Approved
EquileninThe risk or severity of adverse effects can be increased when Olopatadine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Equilin.Approved
ErythromycinThe metabolism of Olopatadine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Olopatadine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Olopatadine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololOlopatadine may decrease the antihypertensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Olopatadine.Approved, Illicit
EstroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Estrone sulfate.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Olopatadine.Approved
Etacrynic acidOlopatadine may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Olopatadine.Approved, Investigational
EthanolOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Olopatadine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Olopatadine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Olopatadine.Approved
Ethyl biscoumacetateOlopatadine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Olopatadine.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Olopatadine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Olopatadine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Olopatadine.Approved
Etidronic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etidronic acid.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Olopatadine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Olopatadine.Approved
EtodolacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etofenamate.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Olopatadine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etoperidone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Olopatadine.Illicit, Vet Approved
EtravirineThe serum concentration of Olopatadine can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Olopatadine is combined with exisulind.Investigational
EzogabineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Felbamate.Approved
FenbufenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fenbufen.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Olopatadine.Approved, Illicit, Withdrawn
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Olopatadine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Olopatadine.Vet Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Olopatadine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fexofenadine.Approved
FleroxacinOlopatadine may increase the neuroexcitatory activities of Fleroxacin.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flibanserin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Olopatadine.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with fluasterone.Investigational
FluconazoleThe metabolism of Olopatadine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Olopatadine.Approved, Illicit
FludrocortisoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fludrocortisone.Approved
FluindioneOlopatadine may increase the anticoagulant activities of Fluindione.Investigational
FlumequineOlopatadine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flumethasone.Approved, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flunarizine.Approved
FlunisolideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flunisolide.Approved, Investigational
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Olopatadine.Approved, Illicit
FlunixinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluorometholone.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Olopatadine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Olopatadine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Olopatadine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flurandrenolide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Olopatadine.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Olopatadine.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Olopatadine.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Olopatadine.Approved
FluvoxamineThe metabolism of Olopatadine can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Olopatadine.Approved, Nutraceutical, Vet Approved
FondaparinuxOlopatadine may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumOlopatadine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Olopatadine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Olopatadine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Olopatadine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Olopatadine.Approved
FosphenytoinThe metabolism of Olopatadine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Olopatadine.Approved, Illicit
FramycetinOlopatadine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideOlopatadine may decrease the diuretic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Olopatadine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Olopatadine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Olopatadine is combined with gabapentin enacarbil.Approved
GabexateOlopatadine may increase the anticoagulant activities of Gabexate.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Olopatadine.Approved, Illicit
GarenoxacinOlopatadine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinOlopatadine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Olopatadine.Approved, Withdrawn
GemifloxacinOlopatadine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinOlopatadine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinOlopatadine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AOlopatadine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GepironeThe risk or severity of adverse effects can be increased when Olopatadine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Olopatadine.Approved, Illicit
GrepafloxacinOlopatadine may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Olopatadine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Olopatadine.Approved, Vet Approved
HE3286The risk or severity of adverse effects can be increased when Olopatadine is combined with HE3286.Investigational
HeparinOlopatadine may increase the anticoagulant activities of Heparin.Approved, Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Olopatadine.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Olopatadine.Approved
HigenamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Higenamine.Investigational
HirulogOlopatadine may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Olopatadine is combined with HMPL-004.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Olopatadine.Approved, Investigational
HydralazineOlopatadine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Olopatadine.Approved, Vet Approved
HydrocodoneOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Olopatadine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Olopatadine.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Olopatadine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
Hygromycin BOlopatadine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Olopatadine is combined with Icatibant.Approved
IdarubicinOlopatadine may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdelalisibThe serum concentration of Olopatadine can be increased when it is combined with Idelalisib.Approved
idraparinuxOlopatadine may increase the anticoagulant activities of idraparinux.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Iloperidone.Approved
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Olopatadine.Approved, Investigational
ImatinibThe metabolism of Olopatadine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Olopatadine.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Olopatadine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Olopatadine.Approved
IndenololOlopatadine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Olopatadine can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Olopatadine.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Indoprofen.Withdrawn
INNO-206Olopatadine may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Olopatadine.Approved, Investigational
IsavuconazoniumThe metabolism of Olopatadine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Olopatadine.Approved, Vet Approved
IsoxicamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Isoxicam.Withdrawn
IsradipineThe metabolism of Olopatadine can be decreased when combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Olopatadine is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Olopatadine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Olopatadine can be increased when it is combined with Ivacaftor.Approved
KanamycinOlopatadine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Kebuzone.Experimental
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Olopatadine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Olopatadine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Olopatadine.Approved
KetoconazoleThe metabolism of Olopatadine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Olopatadine.Approved
LabetalolOlopatadine may decrease the antihypertensive activities of Labetalol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Olopatadine.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Olopatadine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Leflunomide.Approved, Investigational
LepirudinOlopatadine may increase the anticoagulant activities of Lepirudin.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levetiracetam.Approved, Investigational
LevobunololOlopatadine may decrease the antihypertensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Olopatadine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levodopa.Approved
LevofloxacinOlopatadine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Olopatadine.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Olopatadine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Olopatadine.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Olopatadine.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Olopatadine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Olopatadine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Olopatadine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Olopatadine.Illicit
LomefloxacinOlopatadine may increase the neuroexcitatory activities of Lomefloxacin.Approved
LopinavirThe metabolism of Olopatadine can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Olopatadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Olopatadine.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Olopatadine.Approved
LovastatinThe metabolism of Olopatadine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Olopatadine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Loxoprofen.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Olopatadine.Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Olopatadine.Approved, Investigational
LuliconazoleThe serum concentration of Olopatadine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Olopatadine can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Olopatadine.Vet Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Olopatadine.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Magnesium salicylate.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Maprotiline.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Olopatadine.Approved
ME-609The risk or severity of adverse effects can be increased when Olopatadine is combined with ME-609.Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Olopatadine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Meclofenamic acid.Approved, Vet Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Olopatadine.Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mefenamic acid.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Olopatadine.Approved, Nutraceutical, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Meloxicam.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Olopatadine.Approved
MephedroneMephedrone may decrease the sedative activities of Olopatadine.Investigational
MephentermineMephentermine may decrease the sedative activities of Olopatadine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Olopatadine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Olopatadine.Approved, Illicit
MesalazineOlopatadine may increase the nephrotoxic activities of Mesalazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Olopatadine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Olopatadine is combined with Metamizole.Withdrawn
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Olopatadine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Olopatadine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Olopatadine.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Olopatadine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Olopatadine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Olopatadine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Olopatadine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Olopatadine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Olopatadine.Approved
MethotrimeprazineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Olopatadine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Methsuximide.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olopatadine.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Olopatadine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Methylprednisolone.Approved, Vet Approved
MetipranololOlopatadine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Olopatadine.Approved
MetoprololOlopatadine may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideOlopatadine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MetyrosineOlopatadine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Olopatadine.Approved, Illicit
MifepristoneThe serum concentration of Olopatadine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Olopatadine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved, Investigational
MirtazapineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Olopatadine.Approved
MitotaneThe serum concentration of Olopatadine can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mizoribine.Investigational
MMDAMMDA may decrease the sedative activities of Olopatadine.Experimental, Illicit
ModafinilThe serum concentration of Olopatadine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Olopatadine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Olopatadine.Approved
MometasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Olopatadine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Olopatadine.Approved, Investigational
MoxifloxacinOlopatadine may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Olopatadine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mycophenolic acid.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nabumetone.Approved
NadololOlopatadine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinOlopatadine may increase the anticoagulant activities of Nadroparin.Approved
NafamostatOlopatadine may increase the anticoagulant activities of Nafamostat.Investigational
NafcillinThe serum concentration of Olopatadine can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Olopatadine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Olopatadine.Approved
Nalidixic AcidOlopatadine may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Olopatadine is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Olopatadine is combined with NCX 4016.Investigational
NeamineOlopatadine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NefazodoneThe metabolism of Olopatadine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Olopatadine can be decreased when combined with Nelfinavir.Approved
NemonoxacinOlopatadine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinOlopatadine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nepafenac.Approved
NetilmicinOlopatadine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NetupitantThe serum concentration of Olopatadine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Olopatadine can be increased when combined with Nevirapine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Niflumic Acid.Approved
NilotinibThe metabolism of Olopatadine can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nimesulide.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Olopatadine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Olopatadine.Approved, Vet Approved
NorfloxacinOlopatadine may increase the neuroexcitatory activities of Norfloxacin.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Olopatadine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Olopatadine.Approved
OfloxacinOlopatadine may increase the neuroexcitatory activities of Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Olopatadine.Approved, Investigational
OlaparibThe metabolism of Olopatadine can be decreased when combined with Olaparib.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Olopatadine.Approved, Investigational
OlsalazineOlopatadine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Olopatadine.Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Olopatadine.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Olopatadine.Approved, Illicit
OrgoteinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Orgotein.Vet Approved
OrphenadrineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Olopatadine.Investigational
OsimertinibThe serum concentration of Olopatadine can be increased when it is combined with Osimertinib.Approved
OtamixabanOlopatadine may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oxaprozin.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Olopatadine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Olopatadine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Olopatadine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Olopatadine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Olopatadine.Approved, Investigational, Vet Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oxyphenbutazone.Withdrawn
PalbociclibThe serum concentration of Olopatadine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Olopatadine.Approved
PamidronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pamidronate.Approved
ParaldehydeOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Parecoxib.Approved
ParomomycinOlopatadine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Paroxetine.Approved, Investigational
PazufloxacinOlopatadine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinOlopatadine may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololOlopatadine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Olopatadine.Approved, Vet Approved
PentobarbitalThe metabolism of Olopatadine can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateOlopatadine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
PerazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Olopatadine.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Olopatadine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Olopatadine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Olopatadine.Approved
PhenindioneOlopatadine may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Olopatadine can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Olopatadine.Approved
PhenprocoumonOlopatadine may increase the anticoagulant activities of Phenprocoumon.Approved
PhenterminePhentermine may decrease the sedative activities of Olopatadine.Approved, Illicit
PhenylbutazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Olopatadine can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Olopatadine.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Olopatadine.Approved
PindololOlopatadine may decrease the antihypertensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Olopatadine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pipotiazine.Approved
PirarubicinOlopatadine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideOlopatadine may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pirfenidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Piritramide.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Olopatadine.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pizotifen.Approved
PlicamycinOlopatadine may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Olopatadine.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Olopatadine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololOlopatadine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Olopatadine.Approved
PramipexoleOlopatadine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Olopatadine.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prasterone.Approved, Nutraceutical
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Olopatadine.Approved, Illicit
PrednicarbateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Olopatadine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pregnanolone.Investigational
PregnenoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pregnenolone.Experimental
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Olopatadine.Approved
PrimidoneThe metabolism of Olopatadine can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Olopatadine can be increased when it is combined with Probenecid.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Olopatadine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Olopatadine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Olopatadine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Promethazine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Propacetamol.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Olopatadine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Olopatadine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Olopatadine.Approved
PropranololOlopatadine may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Olopatadine.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Olopatadine.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Olopatadine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Olopatadine.Vet Approved
Protein COlopatadine may increase the anticoagulant activities of Protein C.Approved
Protein S humanOlopatadine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeOlopatadine may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Olopatadine.Approved
PrulifloxacinOlopatadine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Olopatadine.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Olopatadine.Approved
PTC299The risk or severity of adverse effects can be increased when Olopatadine is combined with PTC299.Investigational
PuromycinOlopatadine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Olopatadine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Olopatadine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Olopatadine.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Olopatadine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Olopatadine.Approved
RanolazineThe metabolism of Olopatadine can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Olopatadine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Olopatadine.Approved, Withdrawn
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Olopatadine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Olopatadine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Resveratrol.Experimental, Investigational
ReviparinOlopatadine may increase the anticoagulant activities of Reviparin.Approved
RibostamycinOlopatadine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifabutinThe metabolism of Olopatadine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Olopatadine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Olopatadine can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Risedronate.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Olopatadine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ritanserin.Investigational
RitobegronRitobegron may decrease the sedative activities of Olopatadine.Investigational
RitonavirThe metabolism of Olopatadine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanOlopatadine may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Rofecoxib.Investigational, Withdrawn
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Olopatadine.Vet Approved
RopiniroleOlopatadine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Olopatadine.Approved
RosoxacinOlopatadine may increase the neuroexcitatory activities of Rosoxacin.Approved
RotigotineOlopatadine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Olopatadine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Olopatadine.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Olopatadine.Approved
Sage 547The risk or severity of adverse effects can be increased when Olopatadine is combined with Sage 547.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Olopatadine.Experimental
SaquinavirThe metabolism of Olopatadine can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Olopatadine.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Olopatadine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Olopatadine.Approved, Vet Approved
SeratrodastThe risk or severity of adverse effects can be increased when Olopatadine is combined with Seratrodast.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Olopatadine.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Olopatadine.Approved, Vet Approved
SildenafilThe metabolism of Olopatadine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Olopatadine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Olopatadine can be increased when it is combined with Simeprevir.Approved
SisomicinOlopatadine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
SotalolOlopatadine may decrease the antihypertensive activities of Sotalol.Approved
SP1049COlopatadine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinOlopatadine may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinOlopatadine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Olopatadine.Approved
SpironolactoneOlopatadine may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Olopatadine is combined with SRT501.Investigational
St. John's WortThe serum concentration of Olopatadine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Olopatadine can be increased when it is combined with Stiripentol.Approved
StreptomycinOlopatadine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinOlopatadine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Olopatadine.Approved, Investigational
SulfasalazineOlopatadine may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Olopatadine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Olopatadine.Approved
SulodexideOlopatadine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Olopatadine.Approved
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Olopatadine.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Suprofen.Approved, Withdrawn
SuvorexantOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusOlopatadine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Olopatadine.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Olopatadine.Approved
TandospironeThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tasimelteon.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Olopatadine.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Technetium Tc-99m Medronate.Approved
TelaprevirThe metabolism of Olopatadine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Olopatadine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Olopatadine.Approved, Investigational
TemafloxacinOlopatadine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Olopatadine.Approved
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Olopatadine.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Olopatadine.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Olopatadine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Olopatadine.Investigational
ThalidomideOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Olopatadine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Olopatadine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Olopatadine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Olopatadine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiapride.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiaprofenic acid.Approved
TiclopidineThe metabolism of Olopatadine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Olopatadine.Vet Approved
TiludronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiludronate.Approved, Vet Approved
TimololOlopatadine may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tixocortol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Olopatadine.Approved
TobramycinOlopatadine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Olopatadine can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Olopatadine.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Olopatadine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Olopatadine.Approved
TorasemideOlopatadine may decrease the diuretic activities of Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Olopatadine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Olopatadine.Approved
TranilastThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Olopatadine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Olopatadine.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Olopatadine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Olopatadine.Approved, Investigational
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Olopatadine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneOlopatadine may decrease the antihypertensive activities of Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Olopatadine.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Olopatadine.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Olopatadine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Olopatadine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Olopatadine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Olopatadine.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Trisalicylate-choline.Approved
TrovafloxacinOlopatadine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
Uc1010The risk or severity of adverse effects can be increased when Olopatadine is combined with Uc1010.Investigational
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Olopatadine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Olopatadine.Approved, Investigational
ValrubicinOlopatadine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Olopatadine.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Olopatadine.Approved
VenlafaxineThe metabolism of Olopatadine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Olopatadine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Olopatadine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Olopatadine.Approved
WarfarinOlopatadine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranOlopatadine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Olopatadine.Vet Approved
Ym150Olopatadine may increase the anticoagulant activities of Ym150.Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Olopatadine.Approved, Illicit, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zaltoprofen.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ziconotide.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Olopatadine.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Olopatadine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Olopatadine.Vet Approved
Zoledronic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zoledronic acid.Approved
ZolpidemOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zomepirac.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Olopatadine.Approved
ZorubicinOlopatadine may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Olopatadine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Olopatadine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Thomas Bader, Hans-Ulrich Bichsel, Bruno Gilomen, Imelda Meyer-Wilmes, Mark Sundermeier, “Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof.” U.S. Patent US20070232814, issued October 04, 2007.

US20070232814
General References
  1. Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, Mukouyama A: Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002 Apr;88(4):379-97. [PubMed:12046981 ]
  2. Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA: The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996 Winter;12(4):389-400. [PubMed:8951675 ]
  3. Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, Karasawa A, Urayama N, Horikoshi K, Kajita J, Hasegawa M, Taniguchi K, Komada T, Kawamoto Y: Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung. 2004;54(12):809-29. [PubMed:15646365 ]
  4. Ohmori K, Ikemura T, Kobayashi H, Mukouyama A: [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug]. Nihon Yakurigaku Zasshi. 2001 Jul;118(1):51-8. [PubMed:11496828 ]
  5. Kaliner MA, Oppenheimer J, Farrar JR: Comprehensive review of olopatadine: the molecule and its clinical entities. Allergy Asthma Proc. 2010 Mar-Apr;31(2):112-9. doi: 10.2500/aap.2010.31.3317. [PubMed:20406593 ]
External Links
ATC CodesS01GX09R01AC08
AHFS Codes
  • 04:00.00
PDB EntriesNot Available
FDA labelDownload (114 KB)
MSDSDownload (57.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9747
Blood Brain Barrier+0.6925
Caco-2 permeable+0.7249
P-glycoprotein substrateSubstrate0.8607
P-glycoprotein inhibitor IInhibitor0.5948
P-glycoprotein inhibitor IINon-inhibitor0.8196
Renal organic cation transporterInhibitor0.5413
CYP450 2C9 substrateNon-substrate0.7691
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7242
CYP450 1A2 substrateInhibitor0.7906
CYP450 2C9 inhibitorNon-inhibitor0.8316
CYP450 2D6 inhibitorInhibitor0.6567
CYP450 2C19 inhibitorNon-inhibitor0.8466
CYP450 3A4 inhibitorNon-inhibitor0.8222
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8676
Ames testNon AMES toxic0.8032
CarcinogenicityNon-carcinogens0.8499
BiodegradationNot ready biodegradable0.6088
Rat acute toxicity2.7626 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8082
hERG inhibition (predictor II)Inhibitor0.5
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alcon inc
  • Alcon laboratories inc
  • Alcon Laboratories, Inc.
Packagers
Dosage forms
FormRouteStrength
SolutionOphthalmic0.1 %
Solution / dropsOphthalmic1.11 mg/mL
Spray, meteredNasal665 ug/100uL
SprayNasal665 ug/1
SolutionOphthalmic0.2 %
Solution / dropsOphthalmic2 mg/mL
Spray, meteredNasal600 ug/1
Spray, meteredNasal665 ug/1
Solution / dropsOphthalmic1 mg/mL
LiquidOphthalmic0.1 %
SolutionOphthalmic0.7 %
SolutionOphthalmic7 mg/mL
Prices
Unit descriptionCostUnit
Patanol 0.1% Solution 5ml Bottle111.2USD bottle
Pataday 0.2% eye drops52.98USD ml
Patanol 0.1% eye drops21.38USD ml
Patanase 0.6% nasal spray3.83USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1337603 No1995-11-212012-11-21Canada
CA2195094 No2002-02-262016-05-03Canada
US5116863 No1993-12-182010-12-18Us
US5641805 Yes1995-12-062015-12-06Us
US6995186 Yes2004-05-122024-05-12Us
US7402609 Yes2002-12-192022-12-19Us
US7977376 Yes2003-08-022023-08-02Us
US8399508 Yes2003-03-172023-03-17Us
US8791154 No2012-05-192032-05-19Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point248 °CNot Available
water solubilitySolubleNot Available
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0313 mg/mLALOGPS
logP3.99ALOGPS
logP0.75ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.78ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity109.55 m3·mol-1ChemAxon
Polarizability37.44 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzoxepines. These are compounds containing a dibenzoxepine moiety, which consists of two benzene connected by an oxazepine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzoxepines
Sub ClassDibenzoxepines
Direct ParentDibenzoxepines
Alternative Parents
Substituents
  • Dibenzoxepine
  • Alkyl aryl ether
  • Benzenoid
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Tamura T, Masaki S, Ohmori K, Karasawa A: Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice. Pharmacology. 2005 Dec;75(1):45-52. Epub 2005 Jun 7. [PubMed:15942272 ]
  2. Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, Mukouyama A: Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002 Apr;88(4):379-97. [PubMed:12046981 ]
  3. Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA: The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996 Winter;12(4):389-400. [PubMed:8951675 ]
  4. Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, Karasawa A, Urayama N, Horikoshi K, Kajita J, Hasegawa M, Taniguchi K, Komada T, Kawamoto Y: Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung. 2004;54(12):809-29. [PubMed:15646365 ]
  5. Ohmori K, Ikemura T, Kobayashi H, Mukouyama A: [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug]. Nihon Yakurigaku Zasshi. 2001 Jul;118(1):51-8. [PubMed:11496828 ]
  6. Roland PS, Ryan MW, Wall GM: Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older. Expert Opin Pharmacother. 2010 Jun;11(9):1559-67. doi: 10.1517/14656566.2010.485609. [PubMed:20482305 ]
  7. Kaliner MA, Oppenheimer J, Farrar JR: Comprehensive review of olopatadine: the molecule and its clinical entities. Allergy Asthma Proc. 2010 Mar-Apr;31(2):112-9. doi: 10.2500/aap.2010.31.3317. [PubMed:20406593 ]
  8. Roland PS, Marple BF, Wall GM: Olopatadine nasal spray for the treatment of allergic rhinitis. Expert Rev Clin Immunol. 2010 Mar;6(2):197-204. [PubMed:20402382 ]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
S100 protein binding
Specific Function:
Weakly binds calcium but binds zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer. Physiological concentrations of potassium ion antagonize the binding of both divalent cations, especially affecting high-affinity calcium-binding sites. May mediate calcium-dependent regulation on many physiological processes by interacting with other proteins, ...
Gene Name:
S100A1
Uniprot ID:
P23297
Molecular Weight:
10545.755 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
S100A12 is a calcium-, zinc- and copper-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response. Its proinflammatory activity involves recruitment of leukocytes, promotion of cytokine and chemokine production, and regulation of leukocyte adhesion and migration. Acts as an alarmin or a danger associated molecular pattern (DAMP) molecule and st...
Gene Name:
S100A12
Uniprot ID:
P80511
Molecular Weight:
10574.975 Da
References
  1. Kishimoto K, Kaneko S, Ohmori K, Tamura T, Hasegawa K: Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein. Mediators Inflamm. 2006;2006(1):42726. [PubMed:16864903 ]
  2. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Zinc ion binding
Specific Function:
Weakly binds calcium but binds zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer. Physiological concentrations of potassium ion antagonize the binding of both divalent cations, especially affecting high-affinity calcium-binding sites. Binds to and initiates the activation of STK38 by releasing autoinhibitory intramolecular interactions within...
Gene Name:
S100B
Uniprot ID:
P04271
Molecular Weight:
10712.985 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Zinc ion binding
Specific Function:
Plays a role in the export of proteins that lack a signal peptide and are secreted by an alternative pathway. Binds two calcium ions per subunit. Binds one copper ion. Binding of one copper ion does not interfere with calcium binding. Required for the copper-dependent stress-induced export of IL1A and FGF1. The calcium-free protein binds to lipid vesicles containing phosphatidylserine, but not ...
Gene Name:
S100A13
Uniprot ID:
Q99584
Molecular Weight:
11471.095 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Identical protein binding
Specific Function:
May function as calcium sensor and modulator, contributing to cellular calcium signaling. May function by interacting with other proteins, such as TPR-containing proteins, and indirectly play a role in many physiological processes. May also play a role in suppressing tumor cell growth.
Gene Name:
S100A2
Uniprot ID:
P29034
Molecular Weight:
11116.695 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 03:54